Literature DB >> 383418

Combined action of sulphamethoxazole and trimethoprim against clinically-isolated sulphonamide-resistant bacteria.

D Grey, J M Hamilton-Miller, W Brumfitt.   

Abstract

42 strains of gram-negative bacteria, isolated from clinical material, resistant to trimethoprim (TM), sulphamethoxazole (SMZ) or both, have been tested for synergistic sensitivity to TM + SMZ. The combination showed no synergy against strains 'highly resistant' to SMZ (MIC greater than 1 mg/ml). Indifference was invariably observed. However, synergy was seen with strains 'moderately resistant' to SMZ (MIC 100--1,000 microgram/ml). Our results indicate that present techniques for the testing of urinary tract isolates for sensitivity to co-trimoxazole need revision.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 383418     DOI: 10.1159/000237854

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  5 in total

1.  General survey of trimethoprim combinations in the treatment of urinary tract infections.

Authors:  W Brumfitt; J M Hamilton-Miller
Journal:  Infection       Date:  1979       Impact factor: 3.553

Review 2.  Cotrimoxazole. Rationale for re-examining its indications for use.

Authors:  R A Howe; R C Spencer
Journal:  Drug Saf       Date:  1996-04       Impact factor: 5.606

3.  Comparative trial of trimethoprim and co-trimoxazole in recurrent urinary infections.

Authors:  W Brumfitt; J M Hamilton-Miller; H Ludlam; V Damjanovic; R Gargan
Journal:  Infection       Date:  1982 Sep-Oct       Impact factor: 3.553

Review 4.  Co-trimoxazole (trimethoprim-sulfamethoxazole): an updated review of its antibacterial activity and clinical efficacy.

Authors:  G P Wormser; G T Keusch; R C Heel
Journal:  Drugs       Date:  1982-12       Impact factor: 9.546

5.  Co-trimoxazole sensitivity testing: comparison of separate and combined disk agar diffusion techniques.

Authors:  S G Amyes; W A Telfer Brunton
Journal:  J Clin Pathol       Date:  1981-02       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.